Simple Summary Drug resistance is prevalent in many types of cancer and decreases
patient survival. The taxanes are anti-mitotic chemotherapeutic agents, widely used since …

Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …

BACKGROUND: Taxanes are established in the treatment of metastatic breast cancer (MBC)
and early breast cancer (EBC) as potent chemotherapy agents. However, their therapeutic …

Taxanes and anthracyclines are two of the most potent and broadly effective classes of
chemotherapeutic agents. However, resistance to these agents is common and significantly …

One of the primary causes of attenuated or loss of efficacy of cancer chemotherapy is the
emergence of multidrug resistance (MDR). Numerous studies have been published …

Taxanes, mainly paclitaxel and docetaxel, the microtubule stabilizers, have been well known
for being the first-line therapy for breast cancer for more than the last thirty years. Moreover …

Taxanes represent one of the most promising classes of anticancer agents. Unfortunately,
their clinical success has been limited by the insurgence of cellular resistance, mainly …

Despite its good initial response and significant survival benefit in patients with castration-
resistant prostate cancer (CRPC), taxane therapy inevitably encounters drug resistance in …

Abstract Learning Objectives After completing this course, the reader will be able to: Identify
the differences in molecular pharmacology of the taxanes. Describe the impact of the …

Taxanes are amongst the most promising antitumor agents available at hand today, of
increasing importancein Asia given that cancer is now one of the major public health …